Labopharm gets Health Canada nod for tramadol

TORONTO, June 18 (Reuters) - Labopharm Inc. (DDS.TO) said on Monday it expects to begin selling its once-daily pain formula, tramadol, in Canada later this year after it received a Notice of Compliance from Health Canada.

The company said it is in talks to complete a licensing and distribution agreement for the drug, which will see the company retain the right to co-promote the product to certain specialties through its own sales force.

($1=$1.07 Canadian)